Abstract-As previously reported, pretreatment with captopril significantly en hanced pleural exudation of rat carrageenin-induced pleurisy. However, in high molecular weight kininogen-deficient rats (B/N-Katholiek), the pleural exudate volume was significantly less than that of the normal strain (B/N-Kitasato), and captopril pretreatment did not enhance exudation. In the present study, the follow ing additional evidences were demonstrated: 1) Captopril did not increase 6-keto PGF1a level in the deficient strain, but it was significantly increased in the normal strain after captopril treatment; 2) simultaneous administration of soybean trypsin inhibitor with carrageenin markedly suppressed the exudate volume and levels of 6-keto-PGF1a in the normal strain; and 3) indomethacin also suppressed pleural fluid accumulation and the production of arachidonate metabolites. These data suggest that carrageenin causes intrinsic kinin-release through the activation of plasma kallikrein and then in turn, the kinin stimulates the production of arachidonic acid metabolites. Thus these products and kinin may interact to induce more plasma exudation in carrageenin inflammation. The results also indicate that captopril uncovers the effects of bradykinin on exudation and stimulation of arachidonate metabolite production; otherwise, the biological effect of kinin is too slight to produce a clear effect at the initial phase of the inflammation.
In carrageenin induced edema in rats, an involvement of the kallikrein-kinin system has previously been reported (1) (2) (3) . Our previous work also suggested that kinin involvement in rat carrageenin induced pleurisy, since a high molecular weight (HMW)-kininogen deficient rat strain showed significantly lower reactivity in this model (3, 4) . It is well-known that bradykinin stimulates various tissues to release arachidonate metabolites since an early study reported that renal tissue produced a PGE-like substance by the infusion of bradykinin (5) . Although there have been numerous in vitro studies demonstrating that bradykinin stimulates phospholipase(s) to release arachidonic acid and prostaglandins (6, 7) , there is little in vivo data clearly demon strating kinin-stimulation of prostaglandin production at the inflammatory site.
This study demonstrates that arachidonate metabolite production could be induced through the intrinsic kinin release in car rageenin-induced pleurisy by the use of captopril and the kininogen deficient rat strain (8) .
Materials and Methods Animals: Brown Norway Kitasato (B/N-Ki , normal) and Brown Norway Katholiek (B/N Ka, HMW and LMW-kininogens-deficient) rats were bred and kept in the animal labora tory of Kitasato University as previously reported (2) . Sprague-Dawley (SD) rats, 7 9 week-old, were purchased from Shizuoka Experimental Animal Center (Hamamatsu).
Agents: Carrageenin (lambda, Sigma), indomethacin (Sigma), soybean trypsin in hibitor (SBTI, Worthington), pontamine sky blue (Tokyo Kasei) and anti-PGE2 serum (Institut Pasteur Prod.) were purchased. * To whom correspondence should be addressed .
Captopril (Sankyo Pharm. Co.), prostaglan dins and antisera to 6-keto-PGFia (Ono Pharm. Co.) and thromboxane B2 (TXB2) were kind gifts. Rat pleurisy: Production of rat pleurisy and sample collection were previously described (2) . Captopril, 10 mg/kg, was injected intra peritoneally 30 min before the carrageenin injection. SBTI, 0.2 mg/rat, was injected simultaneously with 0.1 ml of 2% carrageenin in saline solution intrapleurally. Indomethacin, 5 mg/kg, suspended in saline solution con taining 2% ethanol, was intraperitoneally injected into rats 30 min before the carrage enin injection.
Radioimmunoassay of arachidonate me tabolites: Arachidonate metabolites in the pleural exudate was extracted through Sep Pak C18 (Waters) and fractionated by H PLC and measured by radioimmunoassay as described previously (9).
Statistical analysis: Statistical analysis of data were carried out by Student's t-test at P<0.01 or P<0.05. Figure 1 illustrates the effect of captopril on carageenin-induced pleurisy at 0.5 to 3 hr in Sprague-Dawley rats. Pleural fluid volume (panel A) and exudation rate (panel B) at 0.5, 1 and 2 hr, but not leukocytes (panel C) were significantly enhanced by pretreatment with captopril. Since enhancement at 1 hr was the most marked, effects of inhibitors were examined on 1 hr-pleurisy with or without pretreatment of captopril. Figure 2 illustrates Fig. 1 . Panels (D), (E) and (F) show the amounts of arachidonate metabolites, 6-oxo-PGF,a, TXB2 and PGE2, respectively, found in the exudate. Rats are divided into 4 groups: C, C-Ca, S-Ca and I-Ca, and numbers used are shown at the tops of the columns in panel (A). Group C is the control group that received saline intraperitoneally 30 min before the carrageenin injection; C-Ca is the group that received captopril, 10 mg/kg, intra peritoneally 30 min before the carrageenin injection; and S-Ca is the group that treated \, ith captopril intraperitoneally as group C-Ca and also received SBT!, 0.2 mg/rat, simultaneously with carrageenin in the pleural cavity; and I-Ca is the group that received indomethacin, 5 rng/kg, intraperitoneally 30 min prior to the carrageenin injection. Other symbols are the same as those in Fig. 1 . Each bracket indicates 2 groups that are compared, and when the difference between these two groups are statistically significant (P<0.05), this is indicated by an asterisk. topril as shown in panels D and E.
Results
The same type of experiment was per formed on a rat strain congenitally deficient in plasma HMW-kininogen and LMW kininogen, B/N-Katholiek. As shown in Fig.  3 , exudate volume at 1 hr of carrageenin pleurisy was less in the deficient strain than in the normal rat. Captopril treatment produced no enhancement in the former strain, whereas in the normal strain, B/N-Ki, it produced enhancement, which was mostly similar to that in SD rats (shown in Fig. 2) . The amount of 6-keto-PGF1a in the exudate of the normal strain increased markedly by captopril treat ment; otherwise, the level was similar to that of B/N-Ka rats.
Discussion
As previously reported, the experimental inflammation in B/N-Katholiek rat was sig nificantly less than that of the normal strain (2, 3) . Captopril treatment markedly enhanced exudation of carrageenin pleurisy at the early phase in the normal strain, but not in the deficient strain, B/N-Ka, as previously reported (2) . A similar result was reported for urate crystal edema in B/N-Katholiek rats in with Wistar rats (10). In the present experiment, the above findings, espe cially the enhancement of inflammation by captopril in the normal strain, were confirmed.
Moreover, the production of 6-keto-PGF,0 in response to captopril was significantly different between the two strains, as shown in Fig. 3 . The features of the normal strain B/N Ki were similar to those of the SD rat except that the level of TXB2 was less in B/N-Ki rats. The above fact indicates that PG12 production in the exudate could be stimulated by in trinsic bradykinin whose biological life could be prolonged by captopril (otherwise, its hall life is less than 10 sec in rat plasma (11, 12)) when the plasma kallikrein-kinin system is possibly activated by carrageenin to produce bradykinin from HMW-kininogen. Further evidence for the role of kinin was the observed suppression of pleural exudation by SBTI, a specific inhibitor of plasma kalllikrein (13). The inhibitor also suppressed the production of 6-keto-PGFia, clearly indicating that the released kinin may stimulate the production of arachidonate metabolites. 
